Clinical Trial Search

Primary: Medication Adherence — 88.1; 96.6; 94.4 percentage of doses taken (pill count)

Primary: Medication Adherence — 94.8; 82.8 percentage of doses taken

Primary: Blood Pressure Medication Adherence — 396; 470 Participants — p=0.0103

Primary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12

Primary: Percent of Participants With Adherence at Month 6 — 91; 40 percent persistent on therapy — p=<0.05

Primary: Time to Next Asthma or COPD Exacerbation up to 182 Days — 172; 161 days to first exacerbation

Primary: Adherence to Statins — 0.55; 0.57; 0.58; 0.38 mMPR as a fraction — p=<.001

Primary: Mean Self-reported Adherence Score (%) Over a One-month Recall — 97.5; 98.2 percentage of adherence score — p=0.52

Primary: Percentage of Adherent Participants — 65; 38 percentage of participants — p==0.004

Primary: Feasibility of Retaining Study Participants Through the 3 Month Trial — 20; 21 Participants

Primary: Intervention Feasibility as Measured by Number of Providers Agreeing to Participate — 6 Participants

Primary: Change in Tenofovir Diphosphate (TFV-DP) Drug Levels — 1230; 1108; 1887; 1084 fmol/punch — p=0.070

Primary: Percentage of Visits With Appropriate Hypertension Management — 34; 69 percentage of patient-clinician visits — p=<=0.001

Primary: Rate of Medication Adherence — 0.76; 0.79; 0.83 percentage of doses taken — p=0.78

Primary: Proportion of Days Covered With Medicine — 0.69 Proportion of days covered with medicine

Primary: Antipsychotic Medication Adherence — 63.9; 75.0 percentage of participants — p=0.03

Primary: Adherence Measured by Sensor by Percentage of Prescribed Medications Taken — 87.5 percentage of prescribed medication

Primary: The Patients' Satisfaction With Chronic Obstructive Pulmonary Disease (COPD) Medical Treatments During a 12-month Observation Period — 64.2; 66.2; 67.1; 75.8 Unit on Scale

Primary: Change in Treatment Non-adherence as Measured by the Tablets Routine Questionnaire (TRQ) (Past Month) — -23.6 percentage of medication not taken — p=<0.001

Primary: Adherence — 91.84; 88.61; 72.55 Percentage of medication taken

Primary: Medication Adherence — 46.2; 42.1 percentage of days covered

Primary: Median Proportion of Days Covered (PDC) at 8-months Post-enrollment — 0.94; 0.88 proportion of days covered (PDC) — p=0.001

Primary: Analyze How Adherence to Treatment Using ASK-20 Questionnaire Influences Level of Asthma Control. — 34; 32 units on a scale — p=0.967

Primary: Change in Treatment Adherence Within the Past Month as Measured by the Tablet Routines Questionnaire — -27.8 units on a scale — p=<.001

Primary: Mean Adherence, as Measured by Electronic Drug Monitors (EDM) — 96.5; 84.5; 96.4; 84.1 percentage of doses taken on time

Primary: Change From Baseline in the Tablet Routine Questionaire (TRQ) "Past Month" Item at 24 Weeks — 21.5; 28.0 percent of medications not taken

Primary: Percentage of Participants With Positive Response on Increased Motivation Using a Self-test at Month 12 — 36.2 Percentage of participants

Primary: Feasibility of AMDD to Improve Medication Adherence Via Completion Rate — 15 participants

Primary: Mean Number of Adherent Sets of Symbicort Puffs Per Day Over the 26-Week Study Period — 1.3; 1.6 Adherent sets of puffs / day — p=<0.001

Primary: Self-Reported 7-Day Point-Prevalence Abstinence — 197; 181; 202; 176 participants — p=.011